Search results for: Value-Based Pricing

Our Contributions to the Economics of Personalised Medicine

7 March 2018

…frameworks, innovations in pricing and cost effectiveness analyses.   Value frameworks   This strand of research considers new elements of value for personalised medicine, value frameworks, and how they could…

An Issues Panel: Developing Cost Effectiveness for Decision Making: What can be Learnt from “Value Based Pricing”?

29 July 2015

…NICE Decision Support Unit, University of Sheffield. It included the following contributions: Adrian Towse presented “Reflections on Value Based Pricing/Assessment” with an overview of the main elements of the Value…

Personalised Medicine: Economic Incentives for Evidence Generation

28 October 2013

…acceptance of the potential for pricing the same drug differently for particular populations as well as pricing for diagnostics that is based on their value to improving care, not just…

Combination Therapies: A Step Forward to the Value Attribution Problem

4 January 2023

…launched), and complete (all value is apportioned to the constituent therapies). The co-authors presented challenges surrounding attributing value to CTs and the proposed outcome-based value attribution framework. The new solution…

Press Release: Proposed International Price Index Effectively Outsources Pharmaceutical Policy Decisions to Other Countries

29 October 2019

…83% and 74%, compared to 100% in the U.S. Furthermore, value-based pricing frameworks are used in setting prices in the Netherlands and Denmark, meaning that the public’s willingness-to-pay for health…

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

21 April 2021

…elements (d). Value-based pricing would be especially beneficial after the initial urgent round of vaccine procurement, whose rapid development and roll out might otherwise be at risk. We advise that…

Making Outcome-based Payments a Reality in the NHS: A Research Collaboration between OHE, RAND Europe and King’s College London

15 May 2018

…through adaptive pathways, analysing data governance requirements for real-world data, and using real-world evidence to facilitate managed entry agreements. Adrian Towse and Nancy Devlin will apply their expertise on value-based…

OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development

2 August 2016

…lessons from the England value-based pricing (VBP) saga in which practical ways of implementing severity and societal impact adjustments to QALYs were identified but rejected; Concluded that moving from listing…

US Pharmaceutical Pricing Policies

What is the importance of US pharmaceutical pricing policies? What is the global impact of US pharmaceutical pricing policies? Why are US pharmaceutical pricing policies a hot topic? Pharmaceutical pricing…